Patents by Inventor Milind Rajopadhye

Milind Rajopadhye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Matrix metalloproteinase inhibitors
    Publication number: 20050047999
    Abstract: Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties;a chelator; and 0-1 linking groups between the targeting moiety and chelator;wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.
    Type: Application
    Filed: August 21, 2003
    Publication date: March 3, 2005
    Inventors: Alan Carpenter, Milind Rajopadhye
  • MATRIX METALLOPROTEINASE INHIBITORS
    Publication number: 20050025702
    Abstract: Thus the present invention describes novel compounds comprising: 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in treatment of diseases associated with MMPs.
    Type: Application
    Filed: February 14, 2001
    Publication date: February 3, 2005
    Inventors: Carl Decicco, David Nelson, John Barrett, Alan Carpenter, Jingwu Duan, Milind Rajopadhye
  • (2S)-2-amino-4-(2-amino-(3,4,5,6-tetrahydropyrimidin-4-yl) butanoyl and its use in cyclic and acyclic peptides
    Patent number: 6818659
    Abstract: The present invention provides a novel amino acid of the formula: and derivatives thereof that are useful as arginine substitutes in biological targeting moieties.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: November 16, 2004
    Assignee: Bristol-Myers Squibb Pharma, Inc.
    Inventor: Milind Rajopadhye
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6818201
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: November 16, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Edward H. Cheesman, Michael Sworin, Milind Rajopadhye
  • Pharmaceuticals for the imaging of angiogenic disorders
    Patent number: 6800273
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: October 5, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6794518
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: September 21, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Milind Rajopadhye, Thomas D. Harris, Edward H. Cheesman
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6743412
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: June 1, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas D. Harris, Milind Rajopadhye
  • (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES
    Publication number: 20040087603
    Abstract: The present invention provides a novel amino acid of the formula: 1
    Type: Application
    Filed: November 6, 2001
    Publication date: May 6, 2004
    Inventor: Milind Rajopadhye
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6689337
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: February 10, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas D. Harris, Milind Rajopadhye
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6683163
    Abstract: The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: January 27, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas D. Harris, Milind Rajopadhye
  • Vitronectin receptor antagonist pharmaceuticals
    Publication number: 20040014964
    Abstract: The present invention describes novel compounds of the formula:
    Type: Application
    Filed: January 21, 2003
    Publication date: January 22, 2004
    Inventors: Edward H. Cheesman, John A. Barrett, Alan P. Carpenter, Milind Rajopadhye, Michael Sworin
  • Vitronectin receptor antagonist pharmaceuticals
    Publication number: 20030232053
    Abstract: The present invention describes novel compounds of the formula:
    Type: Application
    Filed: September 7, 2001
    Publication date: December 18, 2003
    Inventors: Thomas D. Harris, Milind Rajopadhye
  • Matrix metalloproteinase inhibitors
    Patent number: 6656448
    Abstract: Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties;a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: December 2, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Alan P. Carpenter, Jr., Milind Rajopadhye
  • Pharmaceuticals for the imaging of angiogenic disorders
    Publication number: 20030180305
    Abstract: The present invention describes novel compounds of the formula:
    Type: Application
    Filed: January 14, 2003
    Publication date: September 25, 2003
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
  • Imaging thrombus with glycoprotein llb/llla antagonists
    Publication number: 20030152512
    Abstract: This invention relates to a method of using a radiolabeled small molecule antagonist of the platelet IIb/IIIa receptor for the diagnosis of arterial and venous thrombi.
    Type: Application
    Filed: November 13, 2001
    Publication date: August 14, 2003
    Inventors: Milind Rajopadhye, John A. Barrett
  • Vitronectin receptor antagonist pharmaceuticals
    Publication number: 20030143235
    Abstract: The present invention describes novel compounds of the formula:
    Type: Application
    Filed: November 26, 2002
    Publication date: July 31, 2003
    Inventors: Edward H. Cheesman, Michael Sworin, Milind Rajopadhye
  • Radiopharmaceuticals for imaging infection and inflammation
    Publication number: 20030124053
    Abstract: The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.
    Type: Application
    Filed: May 20, 2002
    Publication date: July 3, 2003
    Inventors: John Andrew Barrett, Edward Hollister Cheesman, Thomas David Harris, Shuang Liu, Milind Rajopadhye, Michael Sworin
  • Vitronectin receptor antagonist pharmaceuticals
    Publication number: 20030113336
    Abstract: The present invention describes novel compounds of the formula:
    Type: Application
    Filed: October 26, 2002
    Publication date: June 19, 2003
    Inventors: Thomas D. Harris, John A. Barrett, Alan P. Carpenter,, Milind Rajopadhye
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6569402
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: May 27, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Edward H. Cheesman, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye, Michael Sworin
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6558649
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: May 6, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Edward H. Cheesman, Michael Sworin, Milind Rajopadhye